The Centers for Medicare and Medicaid Services (CMS) announced the agency will limit coverage for the controversial Alzheimer’s drug Aduhelm to seniors enrolled in clinical trials. The decision is intended to protect seniors while the agency gathers more data on whether Aduhelm slows disease progressions in Alzheimer’s patients.
Category: Devon Herrick
Will The FDA ever approve OTC hearing aids?
It’s been nearly five years since President Trump signed into law the Over-the-Counter Hearing Aid Act. The bipartisan bill, introduced by Senators Chuck Grassley (R-Iowa) and Elizabeth Warren (D-Mass.), was intended to make hearing amplification devices much cheaper and more readily accessible. The Act gave the U.S. Food and Drug Administration (FDA) three years to formulate a guidance proposal and an extra six months to collect comments and issue final guidance. Then COVID got in way. Or was it bureaucratic inertia that got in the way. Perhaps it was both.
Why am I not surprised? Teens who abuse drugs don’t stop as adults
Once teenage drug users reach adulthood are they safely past the likelihood of future drug abuse? No, not according to research. A study followed 5,300 teens all the way to age 50.
Should the FDA Require Proof that High-Priced Drugs Actually Work?
An advisory committee at the U.S. Food and Drug Administration (FDA) recently voted against fast-track approval for an experimental drug to treat amyotrophic lateral sclerosis (ALS). ALS is also known as Lou Gehrig’s disease. You can watch the committee meeting, and learn more, in this post.